Hunter Williams
→ profileProtocol systematizer
Top sources by mention density
- 2026-03-31Survodutide & Mazdutide (GLP-1/Glucagon Duo) (11×)
- 2026-03-29Peptide Q&A · March 2025 (2×)
- 2026-03-30Peptide Q&A · February 2026 (1×)
Cautions
- Hunter Williams (2026-03-31): "Survodutide (rougher Phase 2) - 66% nausea, 49% diarrhea, 41% vomiting - 20-24% discontinuation during rapid bi-weekly dose escalation." [email
- Hunter Williams (2026-03-31): "Phase 2 aggressive bi-weekly escalation caused dropouts" and "Phase 3 = 4-week titration intervals + dose flexibility + pause/restart option." [email
- Hunter Williams (2026-03-31): "Likely need to scale down Reta dose before introducing either of these" and "Same GLP-1 pathway but glucagon agonism feels different from GIP." [email
- Hunter Williams (2026-03-30): "you don' want be on eight milligrams a week forever is what I'd say." [library video slug 18:20
- Hunter Williams (2026-03-31): "NOT approved anywhere yet." [email
Taylor Williams
→ profileFemale-focused HRT + peptides
No content captured for this peptide from this expert.
Dr Trevor Bachmeyer
→ profileAcute vs chronic specialist
No content captured for this peptide from this expert.
Ask the Survodutide Librarian
Answers cite Hunter Williams, Taylor Williams, and Dr Trevor Bachmeyer only — no invented content.
Ask a question about Survodutide: dosing, timing, female-specific considerations, acute vs chronic context, stacking, contraindications.
Research educational use only. Not medical advice. Citations only — no invented content.
Disclaimer — For Research Purposes Only
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol. Members who want access can read about the member-owned co-op on our co-op page.